ASH 2020 | Duvelisib for R/R PTCL: updates from the PRIMO trial
Steven Horwitz, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, provides an update on the latest data from the Phase II PRIMO study (NCT03372057) of duvelisib (DUV), an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory peripheral T cell lymphoma (R/R PTCL). Data obtained from the mature dose optimization phase demonstrate that there was a lower rate of early disease progression in the patient group receiving DUV at 75mg BID (n=13) compared to the 25mg BID group (n=20). Initial results of the ongoing dose-expansion phase, in which 25 patients received DUV at 75 mg BID followed by 25 mg BID, indicate an overall response rate (ORR) of 40-50% and reasonable single-agent activity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem. He has consulted, received honorarium from, or participated in advisory boards for; ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Trillium Therapeutics, Verastem, and Vividion Therapeutics.
